EUVIMEDEUVIMED entdecken
Multizentrische Studie

Outcome and feasibility of radiotherapy bridging in large B‐cell lymphoma patients receiving CD19 CAR T in the UK

A Kuhnl iD, C Roddie iD, A A Kirkwood, S Chaganti, J Norman, S Lugthart, W Osborne, A Gibb, C Gonzalez Arias, A Latif, B Uttenthal, F Seymour iD und 16 weitere

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19453 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2024. Verfasst von A Kuhnl und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, King's College Hospital, London, UK. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Immunotherapy, Adoptive. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiotherapy (RT) has potential synergistic effects with chimeric antigen receptor (CAR) T but is not widely used as bridging therapy due to logistical challenges and lack of standardised protocols. We analysed RT bridging in a multicentre national cohort of large B‐cell lymphoma patients approved for 3L axicabtagene ciloleucel or tisagenlecleucel across 12 UK centres. Of 763 approved patients, 722 were leukapheresed, 717 had data available on bridging therapy. 169/717 (24%) received RT bridging, 129 as single modality and 40 as combined modality treatment (CMT). Of 169 patients, 65.7% had advanced stage, 36.9% bulky disease, 86.5% elevated LDH, 41.7% international prognostic index (IPI) ≥3 and 15.2% double/triple hit at the time of approval. Use of RT bridging varied from 11% to 32% between centres and increased over time. Vein‐to‐vein time and infusion rate did not differ between bridging modalities. RT‐bridged patients had favourable outcomes with 1‐year progression‐free survival (PFS) of 56% for single modality and 47% for CMT (1‐year PFS 43% for systemic bridging). This is the largest cohort of LBCL patients receiving RT bridging prior to CAR T reported to date. Our results show that RT bridging can be safely and effectively used even in advanced stage and high‐risk disease, with low dropout rates and excellent outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseImmunotherapy, AdoptiveHumansMaleFemaleMiddle AgedUnited KingdomAgedAdultAntigens, CD19Feasibility StudiesTreatment OutcomeReceptors, Chimeric AntigenAged, 80 and overReceptors, Antigen, T-CellYoung AdultBiological Products

Stichwörter der Autor:innen

cellular therapieslymphoid malignanciesradiotherapy

Substanzen

axicabtagene ciloleucelAntigens, CD19tisagenlecleucelReceptors, Chimeric AntigenReceptors, Antigen, T-CellBiological Products

Autor:innen und Institutionen

  • Department of Haematology, King's College Hospital, London, UK.
  • University College London Hospitals, London, UK.
  • UCL Cancer Institute, University College London, London, UK.
  • Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, UCL, London, UK.
  • Queen Elizabeth Hospital, Birmingham, UK.
  • Department of Haematology, Manchester Royal Infirmary, Manchester, UK.

ORCID-Profile: A Kuhnl, C Roddie, F Seymour, R Prestwich, M O'Reilly, R Sanderson, N G Mikhaeel

Zitieren

APA

Kuhnl, A., Roddie, C., Kirkwood, A. A., Chaganti, S., Norman, J., Lugthart, S., Osborne, W., Gibb, A., Gonzalez Arias, C., Latif, A., Uttenthal, B., Seymour, F., Jones, C., Springell, D., Brady, J. L., Illidge, T., Stevens, A., Alexander, E., Hawley, L., …, & Mikhaeel, N. G. (2024). Outcome and feasibility of radiotherapy bridging in large B‐cell lymphoma patients receiving CD19 CAR T in the UK. British Journal of Haematology. https://doi.org/10.1111/bjh.19453

Vancouver

Kuhnl A, Roddie C, Kirkwood AA, Chaganti S, Norman J, Lugthart S, et al. Outcome and feasibility of radiotherapy bridging in large B‐cell lymphoma patients receiving CD19 CAR T in the UK. British Journal of Haematology. 2024. doi:10.1111/bjh.19453

BibTeX
@article{Kuhnl2024,
  author = {Kuhnl, A and Roddie, C and Kirkwood, A A and Chaganti, S and Norman, J and Lugthart, S and Osborne, W and Gibb, A and Gonzalez Arias, C and Latif, A and Uttenthal, B and Seymour, F and Jones, C and Springell, D and Brady, J L and Illidge, T and Stevens, A and Alexander, E and Hawley, L and O'Rourke, N and Bedi, C and Prestwich, R and Frew, J and Burns, D and O'Reilly, M and Sanderson, R and Sivabalasingham, S and Mikhaeel, N G},
  title = {Outcome and feasibility of radiotherapy bridging in large B‐cell lymphoma patients receiving CD19 CAR T in the UK},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19453}
}
Kostenlos starten →